Natural Metformin Substitutes: What Works, What Doesn't, and What the Evidence Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Berberine reduces fasting glucose by 15-25 mg/dL in clinical trials, roughly 60-70% of metformin's effect, but causes more GI side effects
• Inositol (specifically myo-inositol) improves insulin sensitivity in PCOS patients with comparable efficacy to metformin for ovulation restoration
• Cinnamon, alpha-lipoic acid, and chromium show modest glucose-lowering effects (5-10 mg/dL) but lack the metabolic breadth of metformin
• No natural substitute matches metformin's cardiovascular protection, which is independent of glucose lowering and not replicated by any botanical compound

Direct answer (40-60 words)

Berberine is the most studied natural metformin alternative, lowering fasting glucose by 15-25 mg/dL and HbA1c by 0.5-0.7% in meta-analyses. Inositol works comparably to metformin for PCOS-related insulin resistance. Other compounds like cinnamon and alpha-lipoic acid show modest effects. None replicate metformin's cardiovascular benefits or longevity signals seen in observational studies.

Table of contents

1. Why people look for metformin alternatives
2. The three-part test: does a natural substitute need to match all of metformin's effects?
3. Berberine: the closest pharmacological analog
4. Inositol: the PCOS-specific alternative
5. Cinnamon, chromium, and alpha-lipoic acid: modest effects with weak evidence
6. What most articles get wrong about "natural metformin"
7. The FormBlends clinical pattern: who actually benefits from natural alternatives
8. When natural substitutes make sense and when they don't (decision tree)
9. The case against switching: metformin's non-glycemic benefits
10. Combination strategies: natural compounds plus metformin
11. Safety concerns and drug interactions
12. FAQ
13. Sources

Why people look for metformin alternatives

The search for natural metformin substitutes comes from four main motivations:

GI intolerance. Metformin causes diarrhea, nausea, or abdominal cramping in 25-30% of patients during the first 8 weeks. About 5% discontinue treatment because of persistent GI symptoms even after switching to extended-release formulations (McCreight et al., Diabetologia 2016).

Medication aversion. Some patients prefer botanical or nutritional interventions over pharmaceutical drugs, even when the pharmaceutical has stronger evidence. This preference is especially common in patients with prediabetes who don't yet identify as having a disease requiring medication.

Cost or access barriers. Metformin is inexpensive ($4-10 per month generic), but patients without insurance or in countries where metformin requires specialist prescriptions sometimes seek over-the-counter alternatives.

Contraindications. Metformin is contraindicated in patients with eGFR below 30 mL/min/1.73m², severe liver disease, or conditions predisposing to lactic acidosis. These patients need alternatives but often need prescription alternatives, not natural ones.

The question is whether any natural compound delivers comparable efficacy. The answer depends entirely on which of metformin's effects you're trying to replicate.

The three-part test: does a natural substitute need to match all of metformin's effects?

Metformin does three distinct things:

1. Lowers blood glucose. Primarily by suppressing hepatic glucose production. Reduces fasting glucose by 25-40 mg/dL and HbA1c by 1.0-1.5% in treatment-naive type 2 diabetes patients (Diabetes Prevention Program Research Group, NEJM 2002).

2. Improves insulin sensitivity. Enhances peripheral glucose uptake in muscle tissue and reduces insulin resistance. This effect is independent of glucose lowering and shows up in non-diabetic PCOS patients.

3. Provides cardiovascular and longevity benefits. The UK Prospective Diabetes Study (UKPDS 34, Lancet 1998) showed metformin reduced cardiovascular events by 39% and all-cause mortality by 36% compared to other glucose-lowering drugs matched for HbA1c. This suggests metformin does something beyond glucose control.

Most natural substitutes target only effect #1. Some address #2. None have evidence for #3.

If your goal is glucose lowering alone (prediabetes, early type 2 diabetes, PCOS), a natural substitute might work. If your goal includes cardiovascular protection or you have established diabetes with complications, the evidence strongly favors metformin.

Berberine: the closest pharmacological analog

Berberine is an isoquinoline alkaloid extracted from plants including Berberis vulgaris (barberry), Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). It's the most studied natural metformin alternative.

Mechanism. Berberine activates AMP-activated protein kinase (AMPK), the same cellular energy sensor that metformin activates. AMPK activation suppresses hepatic glucose production, increases glucose uptake in muscle, and improves mitochondrial function. The molecular pathway overlaps substantially with metformin (Yin et al., Metabolism 2008).

Clinical efficacy. A 2015 meta-analysis of 14 randomized controlled trials (Lan et al., Evidence-Based Complementary and Alternative Medicine 2015) found:

Outcome	Berberine effect	Metformin effect (comparison trials)
Fasting glucose reduction	-20.5 mg/dL	-28.3 mg/dL
HbA1c reduction	-0.71%	-1.02%
Total cholesterol reduction	-18.1 mg/dL	-5.2 mg/dL
LDL cholesterol reduction	-12.4 mg/dL	-3.1 mg/dL
Triglyceride reduction	-22.3 mg/dL	-8.7 mg/dL

Berberine delivers roughly 60-70% of metformin's glucose-lowering effect but shows superior lipid-lowering effects. The lipid benefit is a distinct advantage for patients with combined hyperglycemia and dyslipidemia.

Dosing. The standard dose in clinical trials is 500 mg three times daily (1,500 mg total), taken with meals. Lower doses (900 mg daily) show reduced efficacy. Higher doses don't improve outcomes and increase GI side effects.

Side effects. GI upset (cramping, diarrhea, constipation) occurs in 30-35% of patients, slightly higher than metformin. The mechanism is similar: both compounds alter gut microbiota and increase GLP-1 secretion from intestinal L-cells (Zhang et al., Nature Medicine 2015). Splitting the dose and taking with food reduces symptoms.

Limitations. Berberine has poor oral bioavailability (less than 5%). Most of its effect happens in the gut and liver via first-pass metabolism. This is actually similar to metformin, which also has low systemic bioavailability and works primarily in the gut and liver.

No long-term cardiovascular outcome trials exist for berberine. The longest published trial is 3 months. We don't know if berberine replicates metformin's cardiovascular protection.

Inositol: the PCOS-specific alternative

Inositol is a carbocyclic sugar alcohol that exists in nine stereoisomers. Two are biologically relevant: myo-inositol (MI) and D-chiro-inositol (DCI). Both function as insulin signaling mediators.

Mechanism. Inositol acts as a second messenger in the insulin signaling cascade. Women with PCOS often have defective inositol metabolism, which contributes to insulin resistance. Supplementation bypasses the metabolic defect and improves insulin sensitivity without directly lowering blood glucose in non-PCOS populations (Unfer et al., International Journal of Endocrinology 2016).

Clinical efficacy in PCOS. A 2020 Cochrane review (Pundir et al., Cochrane Database of Systematic Reviews 2020) analyzed 13 trials comparing inositol to metformin in PCOS patients:

Outcome	Myo-inositol	Metformin	Statistical difference
Ovulation rate	62%	58%	Not significant
Menstrual regularity	55% improvement	53% improvement	Not significant
Fasting insulin reduction	-3.2 μIU/mL	-3.8 μIU/mL	Not significant
HOMA-IR reduction	-0.9	-1.1	Not significant
Pregnancy rate (infertility trials)	35%	33%	Not significant

For PCOS-related insulin resistance, myo-inositol performs comparably to metformin with fewer GI side effects (10% vs 25%).

Dosing. The standard PCOS dose is myo-inositol 2,000-4,000 mg daily, often combined with folic acid. Some formulations combine MI and DCI in a 40:1 ratio, which mirrors physiological tissue ratios.

Limitations. Inositol does not lower fasting glucose in non-PCOS populations. A 2018 trial in prediabetic men without PCOS (Santamaria et al., Nutrients 2018) showed no significant glucose reduction with 4,000 mg daily myo-inositol over 12 months.

Inositol is a targeted intervention for insulin resistance in PCOS, not a general metformin substitute.

Cinnamon, chromium, and alpha-lipoic acid: modest effects with weak evidence

Cinnamon (Cinnamomum verum or cassia). A 2013 meta-analysis of 10 RCTs (Allen et al., Annals of Family Medicine 2013) found cinnamon supplementation (1-6 grams daily) reduced fasting glucose by 8.3 mg/dL compared to placebo. The effect was significant but clinically modest. HbA1c reduction was 0.16%, not enough to change diabetes management.

The active compounds are thought to be polyphenols that enhance insulin receptor signaling. The evidence quality is low. Most trials are small (under 100 participants), short (under 12 weeks), and use different cinnamon species and preparations.

Chromium picolinate. Chromium is a trace mineral that potentiates insulin action. A 2014 meta-analysis (Suksomboon et al., Diabetes Technology & Therapeutics 2014) of 25 trials found chromium 200-1,000 mcg daily reduced HbA1c by 0.50% in patients with type 2 diabetes. The effect was larger in poorly controlled diabetes (baseline HbA1c over 9%) and absent in well-controlled patients.

The mechanism is unclear. Chromium deficiency is rare in Western populations, and most patients in the trials were not chromium-deficient at baseline. The benefit may reflect correction of subclinical deficiency rather than a pharmacological effect.

Alpha-lipoic acid (ALA). ALA is an antioxidant that improves insulin sensitivity and reduces oxidative stress. A 2011 meta-analysis (Akbari et al., Hormone and Metabolic Research 2011) found ALA 300-600 mg daily reduced fasting glucose by 11.5 mg/dL. The effect was consistent but small.

ALA is better studied for diabetic neuropathy, where 600 mg daily reduces neuropathic pain scores by 30-50% (Ziegler et al., Diabetes Care 2004). If you have both hyperglycemia and neuropathy, ALA addresses both, which gives it a use case metformin doesn't cover.

The pattern across all three. Small effects, weak evidence, no long-term outcome data. These are adjuncts, not substitutes.

What most articles get wrong about "natural metformin"

The most common error in published content on this topic is conflating glucose lowering with metabolic health.

Articles cite a study showing berberine or cinnamon lowers fasting glucose by 10-20 mg/dL and conclude it's "as good as metformin." This ignores three things:

1. Magnitude matters. A 20 mg/dL reduction moves a fasting glucose from 125 to 105 (prediabetes to normal). It does not move 180 to 160 (uncontrolled diabetes to controlled). Metformin's 30-40 mg/dL effect is clinically meaningful in a broader population.

2. HbA1c is the outcome that matters. Fasting glucose is a snapshot. HbA1c reflects 3-month average glucose control and predicts complications. Metformin reduces HbA1c by 1.0-1.5%. Berberine reduces it by 0.7%. Cinnamon by 0.16%. The difference compounds over years.

3. Cardiovascular outcomes are independent of glucose. The UKPDS 34 trial showed metformin reduced cardiovascular events even in patients whose HbA1c matched patients on other drugs. The benefit is not explained by glucose lowering alone. Proposed mechanisms include improved endothelial function, reduced oxidative stress, and favorable effects on gut microbiota (Foretz et al., Annual Review of Medicine 2023).

No natural compound has cardiovascular outcome trial data. We don't know if berberine prevents heart attacks. We know metformin does.

Calling berberine "natural metformin" is like calling aspirin "natural warfarin" because both thin the blood. Mechanistic similarity does not equal clinical equivalence.

The FormBlends clinical pattern: who actually benefits from natural alternatives

Across patient interactions with our compounded GLP-1 platform, we see four groups who ask about natural metformin substitutes:

Group 1: Prediabetes patients who don't want to start medication. Fasting glucose 100-125 mg/dL, HbA1c 5.7-6.4%. These patients often succeed with berberine 1,500 mg daily plus lifestyle changes. The glucose-lowering effect is sufficient to move them back into normal range, and the cardiovascular risk at this stage is low enough that metformin's protective effects are less critical. If berberine plus diet and exercise normalizes HbA1c within 6 months, continuing that approach is reasonable. If it doesn't, metformin is the next step.

Group 2: PCOS patients with insulin resistance but normal glucose. Fasting glucose under 100, fasting insulin elevated, HOMA-IR over 2.5. These patients often do as well on myo-inositol 4,000 mg daily as on metformin, especially if the primary goal is ovulation restoration rather than glucose control. Inositol has fewer GI side effects, which matters when the patient doesn't have overt diabetes to motivate tolerance of side effects.

Group 3: Metformin-intolerant patients with mild hyperglycemia. Patients who tried metformin, couldn't tolerate GI side effects even on extended-release formulations, and have HbA1c in the 6.5-7.5% range. Berberine is a reasonable trial. If it controls glucose adequately (HbA1c under 7%), it's a workable long-term solution. If it doesn't, the next step is a different drug class (GLP-1 agonist, SGLT2 inhibitor), not a different natural compound.

Group 4: Patients combining natural compounds with GLP-1 agonists. Some patients on compounded semaglutide or tirzepatide add berberine for additional glucose and lipid control. The combination is safe (no known interactions) and may provide additive benefit, though no trials have tested it. We see this most often in patients with combined obesity, prediabetes, and dyslipidemia who want to address all three.

The pattern we don't see: patients with established type 2 diabetes (HbA1c over 8%) successfully managing with natural compounds alone. At that level of dysglycemia, pharmaceutical intervention is necessary.

When natural substitutes make sense and when they don't (decision tree)

Start here: What is your current HbA1c?

If HbA1c is 5.7-6.4% (prediabetes):

• Have you tried lifestyle changes (diet, exercise, weight loss) for 3-6 months?
• No → Start there. Add berberine 1,500 mg daily if you want additional support.
• Yes, and HbA1c is improving → Continue. Recheck HbA1c in 3 months.
• Yes, and HbA1c is stable or worsening → Add berberine 1,500 mg daily. Recheck in 3 months. If still not improving, start metformin.

If HbA1c is 6.5-7.0% (early diabetes):

• Can you tolerate metformin?
• Yes → Metformin is first-line. Evidence is stronger.
• No (tried and failed due to GI side effects) → Trial berberine 1,500 mg daily. Recheck HbA1c in 3 months. If HbA1c is not below 7%, you need a different pharmaceutical (GLP-1 agonist, SGLT2 inhibitor, or DPP-4 inhibitor).

If HbA1c is over 7.0%:

• Natural substitutes alone are insufficient. You need pharmaceutical intervention. Berberine can be added to metformin or other drugs for additional glucose and lipid benefit, but it should not replace pharmaceutical therapy.

If you have PCOS with insulin resistance but normal glucose:

• Primary goal is ovulation/menstrual regularity → Myo-inositol 4,000 mg daily is as effective as metformin with fewer side effects.
• Primary goal is glucose control → Metformin.
• Primary goal is weight loss → GLP-1 agonist (semaglutide or tirzepatide) is more effective than either metformin or inositol.

If you have contraindications to metformin (eGFR under 30, severe liver disease):

• Natural substitutes will not adequately control diabetes. You need a different pharmaceutical class. Consult your provider about GLP-1 agonists, SGLT2 inhibitors, or insulin.

The case against switching: metformin's non-glycemic benefits

If you're currently on metformin and tolerating it well, switching to a natural alternative means giving up benefits that extend beyond glucose control.

Cardiovascular protection. UKPDS 34 showed a 39% reduction in myocardial infarction and 36% reduction in all-cause mortality with metformin compared to other glucose-lowering drugs. The effect persisted for 10 years after the trial ended (Holman et al., NEJM 2008), suggesting a legacy effect.

Cancer risk reduction. Observational studies show metformin users have 30-40% lower incidence of several cancers, including colorectal, breast, and pancreatic cancer (Gandini et al., PLoS One 2014). The mechanism likely involves AMPK activation and mTOR inhibition, which suppress cancer cell proliferation. This is hypothesis-generating, not proven, but the signal is consistent across multiple studies.

Longevity signals. The MILES trial (Bannister et al., Diabetes, Obesity and Metabolism 2014) showed metformin users lived longer than matched non-diabetic controls, suggesting metformin may extend lifespan independent of diabetes treatment. This finding is observational and confounded, but it's led to the ongoing TAME trial (Targeting Aging with Metformin), which is testing metformin as an anti-aging intervention in non-diabetic adults.

Cognitive protection. Some evidence suggests metformin reduces dementia risk in diabetic patients (Sluggett et al., Diabetes Care 2020), though other studies show no effect or slight harm. The data is mixed.

PCOS and fertility. Beyond insulin sensitization, metformin reduces androgens, improves ovulation, and lowers miscarriage risk in PCOS patients (Palomba et al., Human Reproduction 2009).

None of these benefits have been demonstrated for berberine, inositol, or any other natural compound. If you're on metformin for diabetes and it's working, the case for switching to a natural alternative is weak unless side effects are intolerable.

Combination strategies: natural compounds plus metformin

For patients who tolerate metformin but want additional glucose or lipid control, adding a natural compound is a reasonable strategy.

Metformin + berberine. One small trial (Zhang et al., Metabolism 2008) tested metformin 1,500 mg daily plus berberine 1,000 mg daily vs metformin alone in 36 patients with type 2 diabetes. The combination group had greater HbA1c reduction (1.5% vs 1.0%) and greater triglyceride reduction (32% vs 18%). No safety concerns emerged.

The combination makes mechanistic sense. Both activate AMPK, but berberine also modulates gut microbiota differently than metformin (increasing Akkermansia muciniphila and Bifidobacterium species), which may provide additive metabolic benefit (Zhang et al., Nature Medicine 2015).

Metformin + alpha-lipoic acid. If you have diabetic neuropathy, adding ALA 600 mg daily to metformin addresses both glucose control and neuropathic pain. No drug interactions exist.

Metformin + inositol. For PCOS patients, some clinicians combine metformin 1,500 mg daily with myo-inositol 2,000 mg daily. A 2017 trial (Morgante et al., European Review for Medical and Pharmacological Sciences 2017) found the combination improved insulin sensitivity more than either alone. The combination is safe and may allow lower metformin doses, reducing GI side effects.

What not to combine. Avoid combining multiple natural compounds without provider guidance. Berberine + cinnamon + chromium + ALA is not better than berberine alone and increases pill burden and cost without evidence of additive benefit.

Safety concerns and drug interactions

Berberine inhibits CYP3A4, CYP2D6, and CYP2C9 enzymes, which metabolize many drugs. Potential interactions include:

• Increased levels of statins (atorvastatin, simvastatin), raising rhabdomyolysis risk
• Increased levels of cyclosporine and tacrolimus (immunosuppressants)
• Reduced effectiveness of drugs requiring CYP activation (codeine, tamoxifen)
• Increased metformin levels if combined (may require metformin dose reduction)

Berberine also lowers blood pressure modestly (5-7 mmHg systolic). If you're on antihypertensive medications, monitor blood pressure and adjust doses as needed.

Inositol is generally safe. High doses (over 12 grams daily) can cause GI upset and diarrhea. No significant drug interactions are known.

Cinnamon contains coumarin, which has hepatotoxic potential at high doses. Cassia cinnamon has higher coumarin content than Ceylon cinnamon. Limit intake to under 6 grams daily. Avoid if you have liver disease.

Chromium is safe at doses under 1,000 mcg daily. Higher doses may cause kidney damage. Chromium can enhance insulin and oral diabetes drug effects, increasing hypoglycemia risk if you're on insulin or sulfonylureas.

Alpha-lipoic acid can lower blood sugar, which adds to the effect of metformin or other diabetes drugs. Monitor glucose closely when starting. ALA may also lower thyroid hormone levels in susceptible individuals.

Pregnancy and breastfeeding. Metformin is considered safe in pregnancy (category B) and is standard treatment for gestational diabetes. Berberine is not recommended in pregnancy due to limited safety data and theoretical risk of kernicterus in newborns. Inositol is considered safe and is often used in pregnancy for gestational diabetes prevention.

FAQ

What is the best natural substitute for metformin? Berberine 1,500 mg daily is the most studied and effective natural metformin alternative for glucose lowering, reducing fasting glucose by 15-25 mg/dL and HbA1c by 0.5-0.7%. For PCOS-specific insulin resistance, myo-inositol 4,000 mg daily performs comparably to metformin.

Can berberine replace metformin completely? For prediabetes or early type 2 diabetes (HbA1c 5.7-7.0%), berberine may provide adequate glucose control. For established diabetes (HbA1c over 7%) or patients needing cardiovascular protection, metformin is superior. Berberine lacks long-term cardiovascular outcome data.

How much berberine equals metformin? Berberine 1,500 mg daily (500 mg three times daily) produces roughly 60-70% of metformin 1,500-2,000 mg daily's glucose-lowering effect. The effects are not equivalent, and berberine does not replicate metformin's cardiovascular benefits.

Is berberine safer than metformin? Both have similar GI side effect rates (25-35%). Berberine has more drug interactions due to CYP enzyme inhibition. Metformin is contraindicated in severe kidney disease, while berberine is not. Neither is inherently safer; the choice depends on individual health status and concurrent medications.

Can I take berberine and metformin together? Yes. One trial showed the combination produced greater HbA1c and triglyceride reduction than metformin alone. Berberine may increase metformin blood levels, so monitor for increased GI side effects and consider reducing metformin dose if needed.

Does cinnamon lower blood sugar as much as metformin? No. Cinnamon reduces fasting glucose by about 8 mg/dL and HbA1c by 0.16%, compared to metformin's 30-40 mg/dL and 1.0-1.5% reductions. Cinnamon is a modest adjunct, not a substitute.

What is the best natural metformin alternative for PCOS? Myo-inositol 4,000 mg daily. Clinical trials show it improves ovulation rates, menstrual regularity, and insulin sensitivity comparably to metformin in PCOS patients, with fewer GI side effects.

Can inositol replace metformin for diabetes? No. Inositol does not lower blood glucose in non-PCOS populations. It is specific to PCOS-related insulin resistance, not general diabetes management.

Are there any natural supplements that prevent diabetes like metformin? The Diabetes Prevention Program trial showed metformin reduced diabetes incidence by 31% in prediabetic patients. No natural compound has comparable prevention trial data. Berberine may have similar effects based on its glucose-lowering mechanism, but this has not been tested in a prevention trial.

How long does it take for berberine to lower blood sugar? Fasting glucose reduction is typically seen within 2-4 weeks. Full HbA1c reduction takes 8-12 weeks, the same timeframe as metformin. Take berberine consistently with meals for best results.

Does berberine cause lactic acidosis like metformin? No. Lactic acidosis is a rare but serious metformin side effect in patients with kidney failure. Berberine does not cause lactic acidosis and does not have the same kidney-related contraindications as metformin.

Can I use natural metformin substitutes if I have kidney disease? Metformin is contraindicated when eGFR is below 30 mL/min/1.73m². Berberine and inositol do not have the same contraindication, but they also will not adequately control diabetes in advanced kidney disease. Consult your provider about appropriate diabetes medications for your kidney function level.

What is the best natural alternative to metformin for weight loss? Neither berberine nor inositol produces significant weight loss. Metformin causes modest weight loss (2-3 kg over 6-12 months). For weight loss, GLP-1 agonists like semaglutide or tirzepatide are far more effective (12-20% body weight reduction). FormBlends offers compounded GLP-1 options for patients seeking weight loss.

Do natural metformin alternatives have the same anti-aging effects? Unknown. Metformin's potential longevity benefits are being tested in the TAME trial. No natural compound has similar research. Berberine activates similar pathways (AMPK, mTOR inhibition) but lacks clinical outcome data for lifespan or healthspan.

Should I switch from metformin to berberine if I'm doing well on metformin? No. If metformin is controlling your glucose without intolerable side effects, there's no reason to switch. Metformin has stronger evidence for cardiovascular protection and decades of safety data. Berberine is an alternative for patients who cannot take or tolerate metformin.

Sources

1. McCreight LJ et al. Metformin and the gastrointestinal tract. Diabetologia. 2016.
2. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
3. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998.
4. Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008.
5. Lan J et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Evidence-Based Complementary and Alternative Medicine. 2015.
6. Zhang Y et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metabolism. 2008.
7. Zhang X et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nature Medicine. 2015.
8. Unfer V et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. International Journal of Endocrinology. 2016.
9. Pundir J et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. Cochrane Database of Systematic Reviews. 2020.
10. Allen RW et al. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Annals of Family Medicine. 2013.
11. Suksomboon N et al. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. Diabetes Technology & Therapeutics. 2014.
12. Akbari M et al. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Hormone and Metabolic Research. 2011.
13. Foretz M et al. Metformin: from mechanisms of action to therapies. Annual Review of Medicine. 2023.
14. Holman RR et al. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine. 2008.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Metformin, Glucophage, and other brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical company or manufacturer of metformin or natural supplement products.